Art Technology Acquisition 3Q 2026: Net income $1.76M — 10-Q Summary

Art Technology Acquisition reported a net income of $1.76M for the quarter, reversing a net loss from the prior-year period. The company earned $2.35M in interest on trust-account securities, offsetting $587,904 in expenses. It has not begun operations and expects no revenue until completing a business combination. As of September 30, 2026, marketable securities totaled $259.6M, with $1.97M in cash and a working capital surplus of $1.76M.

Original reporting
Published Nov 10, 2026, 9:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 9:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Art Technology Acquisition 3Q 2026: Net income $1.76M — 10-Q Summary — source image
Decision brief

The 30-second read

$ARTCNeutralLow
01

Why it matters

The filing provides the first earnings data for ARTC, confirming it has cash and trust assets but no operating revenue. This may reassure some investors while others await a merger announcement.

02

Market read

Micro‑cap SPAC earnings with modest profit; limited immediate market impact without a deal announcement.

03

What to watch

Potential for a large acquisition could dramatically change valuation beyond current modest earnings.

Relevance 5/10Novelty 5/10Timing: after-hours filing

Background

Art Technology Acquisition Corp (ARTC) is a SPAC that has not yet completed a business combination. The filing reports its first quarterly net income and details of its trust account.

Company-level read

Ticker impact

$ARTCNeutralMedium confidence
Context

10-Q filing shows net income of $1.76M and $259.6M trust assets, indicating progress toward a business combination.

Expected impact

likely modest neutral pressure as investors assess combination prospects

Evidence & confidence

Micro‑cap SPAC with modest earnings; market reaction typically muted unless a deal is announced.

Market effects

None significant; SPAC trust balances are standard for this sector.

US market micro‑cap segment only.

Limited to investors tracking SPAC pipeline.

Counterpoint

If the SPAC secures a high‑growth target, the modest cash cushion could support a sharp rally.

Key entities

  • Art Technology Acquisition Corp

    SPAC awaiting business combination

Related articles

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.

$YTRAMed

Yatra Online Inc (YTRA) (Q2 2027) Earnings Call Highlights: Air and Corporate Travel

Yatra Online (YTRA) reported Q2 2027 revenue from operations down 39% YoY to INR2,136M (~$22M) due to lower MICE volumes. Gross margin stayed flat at INR1,255M (~$13M). Adjusted EBITDA swung to negative INR32M (~negative $0.3M). CEO Gupta noted MICE recovery signs, TravelPro and Recap initiatives progress, and AI efficiency gains. Standalone hotels grew 20% YoY. H1 FY27 revenue declined 28% YoY to INR4,015M (~$42M).

$PARKHighAI 8/10

Park Dental Partners Inc (PARK) (Q3 2026) Earnings Call Highlights: Revenue Climbs 6%

Park Dental Partners Inc (PARK) reported Q3 2026 revenue of $64.9M, up 6% YoY, driven by acquisitions and clinical hours. The company acquired Village Family Dental for $39.1M, funded with cash, a small credit line draw, and stock. PARK updated its 2026 revenue outlook to $262M-$265M and adjusted EBITDA to $21.2M-$22.2M. Gross margin declined due to higher salaries and cybersecurity costs. The acquisition adds 47 doctors and expands PARK's footprint to North Carolina.